|
US2019351031A1
|
|
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
WO2017161206A1
|
|
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
KR20170065032A
|
|
Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof and Methods of Using Same
|
|
HUE043847T2
|
|
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
AU2014318545A1
|
|
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
TW201534726A
|
|
Thermally stable PH20 hyaluronidase variants and uses thereof
|
|
WO2014107745A1
|
|
Metal sensitive mutants of matrix metalloproteases and uses thereof
|
|
WO2014062856A1
|
|
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
AU2013202475A1
|
|
SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
|
|
AU2013202000A1
|
|
Extended soluble PH20 polypeptides and uses thereof
|
|
AU2013202011A1
|
|
In vivo temporal control of activatable matrix-degrading enzymes
|
|
AU2013201899A1
|
|
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
AU2013201842A1
|
|
Super fast-acting insulin compositions
|
|
MX2014011965A
|
|
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane.
|
|
SG11201405553YA
|
|
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
CA2861919A1
|
|
Ph20 polypeptide variants, formulations and uses thereof
|
|
EA030440B1
|
|
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
|
CN103974715A
|
|
Stable formulations of a hyaluronan-degrading enzyme
|
|
MX2013014921A
|
|
Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme.
|
|
WO2012109387A1
|
|
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
